IP Library Granted Patent US 12,420,073
Granted Patent B2
US 12,420,073 · App. 17/132,511 · Granted Sep 23, 2025

Biosensor tattoos and uses therefor for biomarker monitoring

Inventors: O. Burak Ozdoganlar (Sewickley, PA); Marcel P. Bruchez (Edgewood, PA); Phil G. Campbell (Pittsburgh, PA); Jonathan W. Jarvik (Pittsburgh, PA); Louis Falo (Wexford, PA); Geza Erdos (Wexford, PA)
Assignees: Carnegie Mellon University; University of Pittsburgh—Of the Commonwealth Systems of Higher Education
A61M37/0015A61K49/0006A61K49/0045A61K49/0097A61M37/0084A61M2037/0061C12N2750/14143C12N2830/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,420,073
App. No.
17/132,511
Granted
Sep 23, 2025
Kind
B2
Abstract

Provided herein are devices and methods used to produce tattoo biosensors that are based on spatially controlled intracutaneous gene delivery of optical reporters driven by specific transcription factor pathways for a given cytokine or other analyte. The biosensors can be specific to a given analyte, or more generically represent the convergence of several cytokines into commonly shared intracellular transcription factor pathways. These biosensors can be delivered as an array in order to monitor multiple cytokines. Biosensor redeployment can enable chronic monitoring from months to years. The tattooed biosensor array of the present invention includes endogenous reporter cells, naturally tuned to each patient's own biology and can be used to reliably measure the state of a patient in real-time.

Claims (29)

1. A microneedle array comprising:

a backing; and

a plurality of microneedles attached to a side of the backing and comprising:

a first nucleic acid comprising a first gene encoding a colorimetric protein under transcriptional control of a vertebrate transcription factor-responsive element (TRE) such that when transfected into a vertebrate cell, the gene is expressed differently in the presence of a vertebrate transcription factor that binds the TRE than in the absence of the transcription factor and the difference in expression of the gene is optically detectable, wherein the first nucleic acid is packaged in an Adeno-associated virus (AAV) transducing particle,

one or more additional, different nucleic acids, with each of the one or more additional, different nucleic acids comprising a second gene encoding a colorimetric protein that is the same or different from the colorimetric protein of the first gene, responsive to the same or different transcriptional control than the first gene, and

a reference reporter gene under transcriptional control of an inducible promotor and encoding a colorimetric protein that is the same or different from the colorimetric protein of the first gene and the second gene,

wherein the microneedles containing the nucleic acids of the first gene, the second gene, and the reference reporter gene are located in discrete, addressable locations within individual or clusters of microneedles, such that when deposited in the skin of a patient, a colorimetric response is spatially patterned.

2. The microneedle array of claim 1 wherein a single microneedle comprises two or more of the different nucleic acids that produce different, separately addressable colorimetric proteins.

3. The microneedle array of claim 2 , wherein the separately addressable colorimetric proteins are two different fluorescent proteins that have distinguishable excitation and/or emission spectra.

4. The microneedle array of claim 1 , wherein at least a portion of the microneedles comprising the nucleic acids, are dissolvable in vivo.

5. The microneedle array of claim 1 , wherein the first nucleic acid is a self-complementary AAV genome.

6. The microneedle array of claim 1 , wherein the colorimetric protein is a fluorescent protein.

7. The microneedle array of claim 6 , wherein which the fluorescent protein is a green, yellow, cyan, red, far-red or near-infrared fluorescent protein.

8. The microneedle array of claim 7 , wherein the fluorescent protein is a far-red or near-infrared fluorescent protein, and the far-red or near-infrared fluorescent protein is one of eqFP578, Katushka, mKate, mNeptune, e2-Crimson, TagRFP657, mCardinal, iRFP670, iRFP682, iRFP702, iRFP713, iRFP720, iSplit, PAiRFP1, PAiRFP2, mCherry, tdTomato, DsRed-Monomer, dsRed-Express2, dsRed-Express, dsRed2, asRed2, mStrawberry, mRuby, mApple, jRed, HcRed1, mRaspberry, dKeima-Tandem, mPlum, AQ143, mIFP, iFP1.4, iFP2.0, or NirFP.

9. The microneedle array of claim 1 , in which the first gene is under transcriptional control of a transcription control sequence comprising the TRE.

10. The microneedle array of claim 9 , wherein the transcription control sequence comprises a minimal cytomegalovirus (CMV) promoter 3′ to the TRE.

11. The microneedle array of claim 1 , wherein the first gene is under transcriptional control of a TRE chosen from: AP-1 TRE, C/EBPalpha TRE, c-Fos TRE, c-Jun TRE, c-Myc TRE, c-Rel TRE, DP-1 TRE, E2F+p107 TRE, E2F-1 TRE, E2F-4/DP-2 TRE, Egr-1 TRE, ErbA TRE, FosB TRE, HIF-1 TRE, HSF1 TRE, INF TRE, JunD TRE, Max1 TRE, NF-κB TRE, N-Myc TRE, p53 TRE, REVERB-alpha TRE, Sp1 TRE, Sp3 TRE, SRF TRE, YY1 TRE, NFAT TRE, FOXO1 TRE, ETS-1 TRE, RELA TRE, STAT1 TRE, STAT2 TRE, STAT1/2 TRE, STAT3 TRE, CREB TRE, IRF1 TRE, and/or SRC-1 TRE.

12. The microneedle array of claim 1 , wherein the second gene is under transcriptional control of a TRE different from that of the first gene, the TRE chosen from one or more of AP-1 TRE, C/EBPalpha TRE, c-Fos TRE, c-Jun TRE, c-Myc TRE, c-Rel TRE, DP-1 TRE, E2F+p107 TRE, E2F-1 TRE, E2F-4/DP-2 TRE, Egr-1 TRE, ErbA TRE, FosB TRE, HIF-1 TRE, HSF1 TRE, INF TRE, JunD TRE, Max1 TRE, NF-κB TRE, N-Myc TRE, p53 TRE, REVERB-alpha TRE, Sp1 TRE, Sp3 TRE, SRF TRE, YY1 TRE, NFAT TRE, FOX01 TRE, ETS-1 TRE, RELA TRE, STAT1 TRE, STAT2 TRE, STAT1/2 TRE, STAT3 TRE, CREB TRE, IRF1 TRE, and/or SRC-1 TRE.

13. The microneedle array of claim 1 , wherein the nucleic acids are placed in layers in the microneedles at a distance from the backing of at least 50 μm.

14. The microneedle array of claim 1 , wherein the nucleic acids are placed in layers in the microneedles, and wherein the microneedles comprise one or more additional nucleic acids, or nucleic acids comprising reporter genes, and optionally constitutive or control reporter genes, drugs, or excipients placed in one or more additional layers.

15. A microneedle array comprising:

a backing;

a plurality of microneedles attached to a side of the backing and extending away from the backing, each of the plurality of microneedles comprising a stem adjacent to the backing and a tip spaced from the backing and comprising at least a first layer arranged a first distance from the backing and a second layer arranged a second distance from the backing;

a first nucleic acid, received within the first layer of the tip of one or more of the plurality of microneedles, the first nucleic acid comprising a first gene encoding a colorimetric protein under transcriptional control of a vertebrate transcription factor-responsive element (TRE) such that when transfected into a vertebrate cell, the gene is expressed differently in the presence of a vertebrate transcription factor that binds the TRE than in the absence of the transcription factor and the difference in expression of the gene is optically detectable, wherein the first nucleic acid is packaged in a viral particle; and

one or more additional, different nucleic acids received within the second layer of the tip of one or more of the plurality of microneedles, each of the one or more additional, different nucleic acids comprising a second gene encoding a colorimetric protein that is the same or different from the colorimetric protein of the first gene, responsive to the same or different transcriptional control than the first gene.

16. The microneedle array of claim 15 , wherein the microneedles containing the nucleic acids of the first gene and the second gene are located in discrete, addressable locations within individual or clusters of microneedles, such that when deposited in the skin of a patient, a colorimetric response is spatially patterned.

17. The microneedle array of claim 15 , wherein the tip comprises a bioerodible material that dissolves in about 30 minutes in vivo.

18. The microneedle array of claim 15 , wherein the stem and the tip of the plurality of microneedles are formed of a bioerodible material, and wherein the bioerodible material of the stem dissolves more quickly than the bioerodible material of the tip.

19. The microneedle array of claim 15 , wherein the first layer and the second layer are formed of different bioerodible materials, such that the first layer dissolves at a different rate than the second layer.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: CARNEGIE-MELON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061657/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: OZDOGANLAR, O. BURAK; BRUCHEZ, MARCEL P.; CAMPBELL, PHIL G.; JARVIK, JONATHAN W.
To: CARNEGIE MELLON UNIVERSITY
Reel/Frame 054739/0895 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: FALO, LOUIS, JR; ERDOS, GEZA
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 054740/0139 →
Continuity (4)
Division 15568327
Provisional Application 62386713 · Dec 10, 2015
Provisional Application 62178954 · Apr 23, 2015
Related Publication 20210187262A1 · Jun 24, 2021
References Cited (132)
US 6093570A · Ferrari et al. · 2000 [cited by applicant]
US 6458587B2 · Ferrari et al. · 2002 [cited by applicant]
US 6951758B2 · Ferrari et al. · 2005 [cited by applicant]
US 7439065B2 · Ferrari et al. · 2008 [cited by applicant]
US 7541188B2 · Conrad · 2009 [cited by examiner]
US 8834423B2 · Falo, Jr. et al. · 2014 [cited by applicant]
US 20020146825A1 · Uhler · 2002 [cited by examiner]
US 20050053971A1 · Chenchik · 2005 [cited by examiner]
US 20050065463A1 · Tobinaga et al. · 2005 [cited by applicant]
US 20050261631A1 · Clarke et al. · 2005 [cited by applicant]
US 20110098651A1 · Falo, Jr. et al. · 2011 [cited by applicant]
US 20140350472A1 · Falo, Jr. et al. · 2014 [cited by applicant]
US 20150126923A1 · Falo, Jr. et al. · 2015 [cited by applicant]
US 20150250739A1 · DeMuth et al. · 2015 [cited by applicant]
WO WO2015189205A1 · 2015 [cited by examiner]
Uhrich, K. E., and D. Abdelhamid. “Biodegradable and bioerodible polymers for medical applications.” Biosynthetic polymers for medical applications. Woodhead Publishing, 2016. 63-83. (Year: 2016). [cited by examiner]
Ward et al. The human cytomegalovirus immediate-early promoter is transcriptionally active in undifferentiated mouse embryonic stem cells. Stem Cells, vol. 20, No. 5, pp. 472-475, Sep. 2002. (Year: 2002). [cited by examiner]
Han et al. A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate. Molecular Genetics and Metabolism, vol. 93,… [cited by examiner]
Shcherbakova et al. Near-infrared fluorescent proteins for multicolor in vivo imaging. Nature Methods, vol. 10, No. 8, pp. 751-754, pp. 1/3-3/3 of Online Methods, and pp. 1-14 of Supplementary Information, Jun. 16, 2013… [cited by examiner]
DeMuth et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nature Materials, vol. 12, pp. 367-376, Jan. 27, 2013. (Year: 2013). [cited by examiner]
Meyer-Ficca, M. L., Meyer, R. G., Kaiser, H., Brack, A. R., Kandolf, R., & Küpper, J.-H. (2004). Comparative analysis of inducible expression systems in transient transfection studies. Analytical Biochemistry, 334(1), 9… [cited by examiner]
Alberts et al., “Rapid transcriptional assay for the expression of two distinct reporter genes by microinjection”, DNA and Cell Biology, 1993, pp. 935-943, vol. 12:10. [cited by applicant]
Allez et al., “Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects”, Journal of Crohn's and Colitis, 2010, pp. 355-366… [cited by applicant]
Altwegg et al., “TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease”, Mediators of Inflammation, 2014, pp. 1-8, vol. 2014, Article ID 172821. [cited by applicant]
Al-Zahrani et al., “Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy”, Expert Opin Drug Deliv., 2012, pp. 541-550, vol. 9:5. [cited by applicant]
Angst et al., “Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: A microdialysis study”, Pain, 2008, pp. 15-27, vol. 139. [cited by applicant]
Aud et al., “Mechanisms of Disease: transcription factors in inflammatory arthritis”, Nature Clinical Practice Rheumatology, 2006, pp. 434-442, vol. 2:8. [cited by applicant]
Averbeck et al., “In situ profiling and quantification of cytokines released during ultraviolet B-induced inflammation by combining dermal microdialysis and protein microarrays”, Experimental Dermatology, 2006, pp. 447-… [cited by applicant]
Ayuso, “Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome”, Molecular Therapy—Methods & Clinical Development, 2016, pp. 1-3, vol. 3:15049. [cited by applicant]
Barton et al., “TL Ymphocyte Effector Mechanisms in the Retina in Posterior Uveitis”, Eye, 1994, pp. 60-65, vol. 8. [cited by applicant]
Bediz et al., “Dissolvable Microneedle Arrays for Intradermal Delivery of Biologics: Fabrication and Application”, Dharm Res, 2014, pp. 117-135, vol. 31:1. [cited by applicant]
Bendtzen et al., “Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies”, Scandinavian Journal of Gastroentero… [cited by applicant]
Bendtzen, “Personalized Medicine: Theranostics {Therapeutics Diagnostics) Essential for Rational Use of Tumor Necrosis Factor-alpha Antagonists”, Discovery Medicine, 2013, pp. 201-211, vol. 15:83. [cited by applicant]
Bengtson et al., “A Differential Fluorescent Receptor for Nucleic Acid Analysis”, Chembiochem, 2014, pp. 228-231, vol. 15:2. [cited by applicant]
Bhinge et al., “Mapping the chromosomal targets of STAT1 by Sequence Tag Analysis of Genomic Enrichment (STAGE)”, Genome Research, 2007, pp. 910-916, vol. 17. [cited by applicant]
Bodenlenz et al., “Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling”, European Journal of Pharmaceutics and Biopharmaceutics, 2012, pp. 635-641, vol. 81. [cited by applicant]
Boukamp et al., “Normal Keratinization in a Spontaneously Immortalized Aneuploid Human Keratinocyte Cell Line”, The Journal of Cell Biology, 1988, pp. 761-771, vol. 106. [cited by applicant]
Bryne et al., “JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update”, Nucleic Acids Research, 2008, pp. D102-D106, vol. 36 (Database issue). [cited by applicant]
Campbell et al., “Tissue engineering with the aid of inkjet printers”, Expert Opinion on Biological Therapy, 2007, pp. 1123-1127, vol. 7:8. [cited by applicant]
Camporeale et al., “IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?”, Frontiers in Bioscience (Landmark Ed), 2012, pp. 2306-2326, vol. 17. [cited by applicant]
Caprioli et al., “Cytokine Therapies in Crohn's Disease: Where are We Now and where should We Go?”, Inflammation & Allergy—Drug Targets, 2011, pp. 47-53, vol. 10. [cited by applicant]
Caprioli et al., “Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases”, British Journal of Pharmacology, 2012, pp. 820-828, vol. 165. [cited by applicant]
Chan et al., “Comparison of IRES and F2A-Based Locus-Specific Multicistronic Expression in Stable Mouse Lines”, PLoS One, 2011, pp. 1-11, vol. 6:12. [cited by applicant]
Chen et al., “A General System for Automatic Biomedical Image Segmentation Using Intensity Neighborhoods”, International Journal of Biomedical Imaging, 2011, pp. 1-13, vol. 2011. [cited by applicant]
Cheng et al., “Principles Of Regulatory Information Conservation Between Mouse And Human”, Nature, 2014, pp. 371-375, vol. 515:7527. [cited by applicant]
Chosdol et al., “Nuclear Factors Linking Cancer and Inflammation”, Nuclear Signaling Pathways and Targeting Transcription in Cancer. Cancer Drug Discovery and Development. Humana Press. New York, NY, 2014, pp. 121-154. [cited by applicant]
Chtarto et al., “An Adeno-Associated Virus-Based Intracellular Sensor of Pathological Nuclear Factor-KB Activation for Disease-Inducible Gene Transfer”, PLOS ONE, 2013, pp. 1-15, vol. 8:1. [cited by applicant]
Chtarto et al., “Tetracycline-inducible transgene expression mediated by a single AAV vector”, Gene Therapy, 2003, pp. 84-94, vol. 10. [cited by applicant]
Cooper et al., “Inkjet-Based Biopatterning of Bone Morphogenetic Protein-2 to Spatially Control Calvarial Bone formation”, Tissue Engineering: Part A, 2010, pp. 1749-1759, vol. 6:5. [cited by applicant]
Coulman et al., “Minimally invasive cutaneous delivery of macromolecules and plasmid DNA via microneedles”, Current Drug Delivery, 2006, pp. 65-75, vol. 3. [cited by applicant]
Deyrieux et al., “In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line”, Cytotechnology, 2007, pp. 77-83, vol. 54. [cited by applicant]
Ding et al., “Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases”, Reviews on Recent Clinical Trials, 2006, pp. 193-200, vol. 1. [cited by applicant]
Ding et al., “Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements”, PNAS, 2013, pp. 6771-6776, vol. 110:17. [cited by applicant]
Ellis et al. “A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype”, Virolog… [cited by applicant]
Euskirchen et al., “Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array- and sequencing-based technologies”, Genome Research, 2007, pp. 898-909, vol. 17. [cited by applicant]
Ferguson et al., “Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies”, Proteomics, 2005, pp. 566-571, vol. 5. [cited by applicant]
Filonov et al., “Bright and stable near-infrared fluorescent protein for in vivo imaging”, Nat Biotechnol, 2012, pp. 757-761, vol. 29:8. [cited by applicant]
Gallagher et al., “Biological response modifier therapy for refractory childhood uveitis”, Br J Ophthalmol, 2007, pp. 1341-1344, vol. 91. [cited by applicant]
Gene Synthesis Handbook, Second Edition, GenScript USA, Inc., 2014. [cited by applicant]
Genovese et al., “Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study”, Ann Rheum Dis, 2014, pp. 1607-16… [cited by applicant]
Gilmore et al., “NF-κB: where did it come from and why?”, Immunological Reviews, 2012, pp. 14-35, vol. 246. [cited by applicant]
Gray et al., “Production of Recombinant Adeno-Associated Viral Vectors and Use in In Vitro and In Vivo Administration”, Curr Protoc Neurosci., 2011, pp. 1-36, Chapter: Unit 4.17. [cited by applicant]
Grigorov et al., “Rapid Titration of Measles and Other Viruses: Optimization with Determination of Replication Cycle Length”, PLoS One, 2011, pp. 1-12, vol. 6:9. [cited by applicant]
Guo et al., “Rapid and simplified purification of recombinant adeno-associated virus”, J Virol Methods, 2012, pp. 139-146, vol. 183:2. [cited by applicant]
Hadam et al., “Managing risks of TNF inhibitors: An update for the internist”, Cleveland Clinic Journal of Medicine, 2014, pp. 115-127, vol. 81:2. [cited by applicant]
Halter et al., “Automated Live Cell Imaging of Green Fluorescent Protein Degradation in Individual Fibroblasts”, Cytometry Part A, 2007, pp. 827-834, vol. 71A. [cited by applicant]
Hareendran et al., “Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them”, Reviews in Medical Virology, 2013, pp. 399-413, vol. 23. [cited by applicant]
Heinz et al., “Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities”, Mol Cell, 2010, pp. 576-589, vol. 38:4. [cited by applicant]
Herberg et al., “Inkjet-based biopatterning of SDF-1beta augments BMP-2-induced repair of critical size calvarial pone defects in mice”, Bone, 2014, pp. 95-103, vol. 67. [cited by applicant]
Hofmann et al., “Efficient gene transfer into human hepatocytes by baculovirus vectors”, Proc. Natl. Acad. Sci. USA, 1995, pp. 10099-10103, vol. 92. [cited by applicant]
Jia et al., “Electrochemical Tattoo Biosensors for Real-Time Noninvasive Lactate Monitoring in Human Perspiration”, Analytical Chemistry, 2013, pp. 6553-6560, vol. 85. [cited by applicant]
Tincani et al., “Inflammatory molecules: a target for treatment of systemic autoimmune diseases”, Autoimmunity Reviews, 2007, pp. 1-7, vol. 7. [cited by applicant]
Voorhees et al., “A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma”, Br J Haematol, 2013, pp. 357-366, vol. 161:3. [cited by applicant]
Wang et al., “Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors”, Genome Research, 2012, pp. 1798-1812, vol. 22. [cited by applicant]
Wen et al., “The Role of the Transcription Factor CREB in Immune Function”, J Immunol, 2010, pp. 6413-6419, vol. 185. [cited by applicant]
Wieder et al., “Optimization of Reporter Cells for Expression Profiling in a Microfluidic Device”, Biomedical Microdevices, 2005, pp. 213-222, vol. 7:3. [cited by applicant]
Xia et al., “In vitro- and In Vivo-Induced Transgene Expression in Human Embryonic Stem Cells and Derivatives”, Stem Cells, 2008, pp. 525-533, vol. 26:2. [cited by applicant]
Xiao et al., “Quantitative 3D Tracing of Gene-delivery Viral Vectors in Human Cells and Animal Tissues”, Molecular Therapy, 2012, pp. 317-328, vol. 20:2. [cited by applicant]
Xu et al., “Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells”, Cancer Letters, 2014, pp. 172-178, vol. 343. [cited by applicant]
Yokota et al., “Pathogenesis of Systemic Inflammatory Diseases in Childhood: Lessons From Clinical Trials of Anti-Cytokine Monoclonal Antibodies for Kawasaki Disease, Systemic Onset Juvenile Idiopathic Arthritis, and Cr… [cited by applicant]
Zhou et al., “Cytokine biosensors: the future of infectious disease diagnosis?”, Expert Rev. Anti Infect Ther, 2012, pp. 1079-1081, vol. 10:0. [cited by applicant]
Zhu et al., “Electrochemical Sensors and Biosensors Based on Nanomaterials and Nanostructures”, Analytical Chemistry, 2014, pp. 230-249, vol. 87. [cited by applicant]
Jiang et al., “Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR”, Gene Therapy, 2004, pp. 1057-1067, vol. 11. [cited by applicant]
Jones et al., “Who Should Receive Biologic Therapy for IBD? The Rationale for the Application of a Personalized Approach”, Gastroenterol Clin North Am, 2014, pp. 425-440, vol. 43. [cited by applicant]
Kang et al., “Therapeutic uses of anti-interleukin-6 receptor antibody”, International Immunology, 2014, pp. 21-29, vol. 27:1. [cited by applicant]
Keswani et al., “Pseudotyped Adeno-associated Viral Vector Tropism and Transduction Efficiencies in Murine Wound Healing”, Wound Repair Regen, 2012, pp. 592-600, vol. 20:4. [cited by applicant]
Kim et al., “Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping”, Nat Biotechnol, 2004, pp. 93-97, vol. 22:1. [cited by applicant]
Koller, “Targeted therapy in rheumatoid arthritis”, Wien Med Wochenschr, 2006, pp. 53-60, vol. 156:1-2. [cited by applicant]
Korkmaz et al., “Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays”, Acta Biomaterialia, 2015, pp. 96-105, vol. 24. [cited by applicant]
Kupetsky et al., “Anti-cytokine therapy in the treatment of psoriasis”, Cytokine, 2013, pp. 704-712, vol. 61. [cited by applicant]
Lallemand et al., “Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFa antagonists”, Journal of Immunological Methods, 2011, pp. 229-239, vol. 373. [cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome”, Blood, 2014, pp. 188-195, vol. 124:2. [cited by applicant]
Mandrup-Poulsenon, “Interleukin-1 antagonists for diabetes”, Expert Opinion on Investigational Drugs, 2013, pp. 965-979, vol. 22:8. [cited by applicant]
Marshall et al., “Near-Infrared Fluorescence Imaging in Humans with Indocyanine Green: A Review and Update”, Open Surg Oncol J., 2012, pp. 12-25, vol. 2, No. 2. [cited by applicant]
Mattocks et al., “A standardized framework for the validation and verification of clinical molecular genetics tests”, European Journal of Human Genetics, 2010, pp. 1276-1288, vol. 18. [cited by applicant]
Maude et al., “Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies”, Cancer J, 2014, pp. 119-122, vol. 20:2. [cited by applicant]
Meglinski et al., “Quantitative assessment of skin layers absorption and skin reflectance spectra simulation in the visible and near-infrared spectral regions”, Physiological Measurement, 2002, pp. 741-753, vol. 23:4. [cited by applicant]
Merten et al., “Current issues in adeno-associated viral vector production”, Gene Therapy, 2005, pp. S51-S61, vol. 12. [cited by applicant]
Milman et al., “Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis”, Clinical Biochemistry, 2010, pp. 1309-1314, vol. 43. [cited by applicant]
Monaco et al., “Anti-TNF therapy: past, present and future”, International Immunology, 2014, pp. 55-62, vol. 27:1. [cited by applicant]
Monteleone et al., “Targets for new immunomodulation strategies in inflammatory bowel disease”, Autoimmunity Reviews, 2014, pp. 11-14, vol. 13. [cited by applicant]
Morozova et al., “Far-Red Fluorescent Protein Excitable with Red Lasers for Flow Cytometry and Superresolution STED Nanoscopy”, Biophysical Journal, 2010, pp. L13-L15, vol. 99. [cited by applicant]
Muller-Ladner, et al., “Role of Nuclear Factor κB in Synovial Inflammation”, Current Rheumatology Reports, 2002, pp. 201-207, vol. 4. [cited by applicant]
Nograles et al., “Anti-cytokine therapies for psoriasis”, Experimental Cell Research, 2011, pp. 1293-1300, vol. 317. [cited by applicant]
Papoutsaki et al., “Treatment of Psoriasis and Psoriatic Arthritis”, Biodrugs, 2013, pp. 3-12, vol. 27:1. [cited by applicant]
Perabo et al., “Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism”, Journal of Virology, 2006, pp. 7265-7269, vol. 80:14. [cited by applicant]
Piatkevich et al., “Guide to Red Fluorescent Proteins and Biosensors for Flow Cytometry”, Methods Cell Biol., 2011, pp. 431-461, vol. 102. [cited by applicant]
Pras et al., “Intraocular Inflammation in Autoimmune Diseases”, Seminars in Arthritis and Rheumatism, 2004, pp. 602-609, vol. 34. [cited by applicant]
Prausnitz et al., “Microneedle-based vaccines”, Curr Top Microbiol Immunol, 2009, pp. 369-393, vol. 333. [cited by applicant]
Prelog, “Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies”, Clinical & Cellular Immunology, 2013, pp. 1-10, vol. S6. [cited by applicant]
PscAAV-MCS Expression Vector, Product Data Sheet, Cell Biolabs, Inc., San Diego, California (2015). [cited by applicant]
Pusztai et al., “Clinical trial design for microarray predictive marker discovery and assessment”, Annals of Oncology, 2004, pp. 1731-1737, vol. 15. [cited by applicant]
Qin et al., “Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter”, PLoS One, 2010, pp. 1-4, vol. 5:5. [cited by applicant]
Qiu et al., “The Interaction of Heparin Sulfate and Adeno-Associated Virus 2”, Virology, 2000, pp. 137-147, vol. 269. [cited by applicant]
Quan et al., “Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch”, Clinical and Vaccine Immunology, 2013, pp. 1433-1439, vol. 20:9. [cited by applicant]
Reynolds et al., “Emerging immunotherapies for rheumatoid arthritis”, Human Vaccines & Immunotherapeutics, 2014, pp. 822-837, vol. 10:4. [cited by applicant]
Rosenbloom et al., “In vitro and in vivo protein sampling by combined microdialysis and ultrafiltration”, Journal of Immunological Methods, 2006, pp. 55-68, vol. 309. [cited by applicant]
Rossi et al., “Interleukin-6 as a Therapeutic Target”, Clinical Cancer Research, 2015, pp. 1248-1257, vol. 21:6. [cited by applicant]
Salgo et al., “Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy”, Experimental Dermatology, 2011, pp. 130-133, vol. 20. [cited by applicant]
Sallach et al., “Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy”, Molecular Therapy, 2014, pp. 929-939, vol. 22:5. [cited by applicant]
Samulski et al., “AAV-Mediated Gene Therapy for Research and Therapeutic Purposes”, Annual Review of Virology, 2014, pp. 427-451, vol. 1. [cited by applicant]
Shcherbakova et al., “Near-infrared fluorescent proteins for multicolor in vivo imaging”, Nat Methods, 2013, pp. 751-754, vol. 10:8. [cited by applicant]
Shu et al., “Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome”, Science, 2009, pp. 804-807, vol. 324:5928. [cited by applicant]
Sikorski et al., “STAT1 as a central mediator of IFNy and TLR4 signal integration in vascular dysfunction”, JAK-STAT, 2012, pp. 241-249, vol. 1:4. [cited by applicant]
Sjogren et al., “Are Cutaneous Microdialysis Cytokine Findings Supported by End Point Biopsy Immunohistochemistry Findings?”, AAPS Journal, 2010, pp. 741-749, vol. 12:4. [cited by applicant]
Sjogren et al., “Cutaneous Microdialysis: Cytokine Evidence for Altered Innate Reactivity in the Skin of Psoriasis Patients?”, AAPS Journal, 2012, pp. 187-195, vol. 14:2. [cited by applicant]
Srivastava et al., ““Smart tattoo” Glucose Biosensors and Effect of Coencapsulated Anti-Inflammatory Agents”, Journal of Diabetes Science and Technology, 2011, pp. 76-85, vol. 5:1. [cited by applicant]
Steenholdt et al., “Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Tria… [cited by applicant]
Steenholdt et al., “Cut-off levels and diagnostic accuracy of infliximab trough levels and antiinfliximab antibodies in Crohn's disease”, Scandinavian Journal of Gastroenterology, 2011, pp. 310-318, vol. 46:3. [cited by applicant]
Steenholdt, “Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease”, Danish Medical Journal, 2013, pp. 1-24, vol. 6… [cited by applicant]
Swindell et al., “Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites”, Clinical and translational medicine, 2015, pp. 1/21-3/21, vol. 4:13. [cited by applicant]
Tanaka et al., “Image-Guided Oncologic Surgery Using Invisible Light: Completed Pre-Clinical Development for Sentinel Lymph Node Mapping”, Ann Surg Oncol., 2006, pp. 1671-1681, vol. 13:12. [cited by applicant]